Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Advanced Composites
LeftNav
Aerospace
LeftNav
Amorphous Metal Structures
LeftNav
Analysis and Simulation
LeftNav
Asbestos and Substitutes
LeftNav
Associations, Research Organisations and Universities
LeftNav
Automation Equipment
LeftNav
Automotive
LeftNav
Biomaterials
LeftNav
Building Materials
LeftNav
Bulk Handling and Storage
LeftNav
CFCs and Substitutes
LeftNav
Company
LeftNav
Components
LeftNav
Consultancy
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Manufacturing Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
 
News

Eastman and Johnson Matthey partner on Chiral ligand marketing

Eastman Chemical Company : 03 November, 2003  (New Product)
Eastman Chemical Company has entered into an agreement with Johnson Matthey Catalysts to collaborate on the marketing of Eastman
Eastman Chemical Company has entered into an agreement with Johnson Matthey Catalysts to collaborate on the marketing of Eastman’s proprietary BoPhoz chiral ligands. The arrangement enables both companies to promote and supply BoPhoz ligands throughout all segments of the chemical industry.

Johnson Matthey, which has a broad chiral capability of its own, brings a global reach to the alliance, as well as a track record of excellence in the field of catalysis. As part of the agreement, Eastman will source platinum group metals and catalyst precursors used in preparation of BoPhoz catalysts exclusively from Johnson Matthey.

“Eastman has developed an excellent chiral technology position through our BoPhoz family of ligands, which has already generated significant interest in the market place,” said Dr. Julian Parratt, business development manager, pharmaceuticals in Eastman’s Performance Chemical Business Organization. “We believe that this alliance will further the reach and scope of the technology through Johnson Matthey’s recognized excellence in the fields of chiral and achiral catalysis.”

“We are delighted with the agreement as Johnson Matthey’s Catalysis and Chiral Technologies (CCT) business is committed to providing the most extensive technology available in asymmetric catalysis,” said Dr. Martin Durney, vice president of JM CCT. “The addition of the BoPhoz ligand is a key part of our strategy to offer cost effective asymmetric hydrogenation solutions to our pharmaceutical and fine chemicals customers”.

The BoPhoz family of chiral ligands possesses a unique phosphine-aminophosphine substructure that imparts attributes not commonly found in other chiral catalysts. Among those attributes are:

Shelf stability: BoPhoz chiral ligands show a surprising degree of shelf stability, even at ambient temperature and in the presence of air.
High enantioselectivity: Asymmetric hydrogenation reactions conducted with BoPhoz chiral ligands typically show enantiomeric excesses equal to or higher than any competitive materials.
Ease of use: BoPhoz chiral ligands require no elaborate protection from the atmosphere, unlike other comparable materials.
Cost-effectiveness: BoPhoz ligands are easily prepared and can be readily scaled up from lab to pilot to commercial quantities.
Application: BoPhoz chiral ligands are particularly effective in the preparation of a wide variety of chiral amino acid derivatives.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   Â© 2012 NewMaterials.com
Netgains Logo